Nykredit A S Takes Position in Teva Pharmaceutical Industries Ltd. $TEVA

Key Points

• Nykredit A S initiated a $11.5 million position in Teva during the second quarter by purchasing 340,196 shares. Institutional investors collectively own approximately 54.05% of TEVA.
• Teva’s recent UZEDY and TEV-'749 data point to potential growth in its neuroscience portfolio, though TEV-'749 remains subject to FDA approval and the findings include company-sponsored or post hoc analyses.
• Analyst sentiment is largely positive: ten analysts rate TEVA a Buy and one rates it Hold, producing a “Moderate Buy” consensus and an average price target of $43.10. Shares opened at $39.11, near their 52-week high of $39.70.

Nykredit A S bought a new stake in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund bought 340,196 shares of the company's stock, valued at approximately $11,526,000.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Harel Insurance Investments & Financial Services Ltd. increased its stake in Teva Pharmaceutical Industries by 2.2% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 45,956,714 shares of the company's stock valued at $1,384,216,000 after purchasing an additional 1,004,941 shares in the last quarter. Clal Insurance Enterprises Holdings Ltd increased its position in Teva Pharmaceutical Industries by 18.8% in the 4th quarter. Clal Insurance Enterprises Holdings Ltd now owns 37,404,106 shares of the company's stock valued at $1,171,378,000 after buying an additional 5,917,423 shares in the last quarter. WCM Investment Management LLC increased its position in Teva Pharmaceutical Industries by 191.4% in the 1st quarter. WCM Investment Management LLC now owns 40,820,600 shares of the company's stock valued at $1,157,264,000 after buying an additional 26,813,522 shares in the last quarter. Norges Bank acquired a new position in Teva Pharmaceutical Industries during the 4th quarter worth approximately $1,098,060,000. Finally, Geode Capital Management LLC raised its stake in Teva Pharmaceutical Industries by 3.4% during the 4th quarter. Geode Capital Management LLC now owns 10,326,504 shares of the company's stock worth $320,295,000 after buying an additional 336,629 shares during the period. 54.05% of the stock is owned by institutional investors.

Teva Pharmaceutical Industries News Roundup

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: UZEDY real-world data support commercial momentum. Teva reported that UZEDY improved treatment adherence and persistence in schizophrenia compared with other long-acting injectables. Patients also had fewer emergency-room visits and hospitalizations, while estimated direct healthcare savings exceeded $1,000 per patient per month. In bipolar I disorder, patients switching to UZEDY had a lower treatment-failure rate than those remaining on oral antipsychotics. UZEDY real-world data
• Positive Sentiment: TEV-'749 data bolster the pipeline ahead of an FDA decision. In a post hoc analysis of the Phase 3 SOLARIS trial, 56% of participants achieved stabilization, only 4% of stabilized patients relapsed, and 21% of those treated for at least six months met remission criteria. The once-monthly olanzapine injection could improve adherence versus daily oral treatment, with an FDA decision expected in the fourth quarter of 2026. TEV-'749 SOLARIS data
• Positive Sentiment: AUSTEDO appears aligned with physician priorities. A study of 489 healthcare professionals found that drowsiness risk, short-term symptom improvement, drug interactions and long-term response data were key factors in tardive dyskinesia treatment selection. AUSTEDO was the most closely aligned option across the patient profiles studied, potentially supporting prescriptions for Teva’s established neuroscience portfolio. AUSTEDO physician-preference study
• Neutral Sentiment: The UZEDY and TEV-'749 findings were company-sponsored presentations and include observational or post hoc analyses, so their commercial impact remains dependent on physician adoption, reimbursement and regulatory approval.
• Negative Sentiment: TEV-'749 remains investigational and could fail to receive FDA approval. In addition, reported insider activity shows selling rather than buying by Teva executives, which may temper investor enthusiasm even as institutional ownership has been mixed.

Analyst Upgrades and Downgrades

TEVA has been the subject of several recent research reports. Piper Sandler boosted their price objective on Teva Pharmaceutical Industries from $42.00 to $44.00 and gave the company an "overweight" rating in a report on Tuesday, July 28th. UBS Group raised their price objective on shares of Teva Pharmaceutical Industries from $42.00 to $48.00 and gave the company a "buy" rating in a research note on Friday, September 4th. Barclays lifted their price objective on shares of Teva Pharmaceutical Industries from $40.00 to $42.00 and gave the company an "overweight" rating in a report on Wednesday, August 12th. Leerink Partners assumed coverage on shares of Teva Pharmaceutical Industries in a research report on Wednesday, September 9th. They set an "outperform" rating and a $45.00 target price for the company. Finally, Wall Street Zen lowered shares of Teva Pharmaceutical Industries from a "buy" rating to a "hold" rating in a report on Sunday, July 12th. Ten analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $43.10.

Teva Pharmaceutical Industries Price Performance

TEVA opened at $39.11 on Monday. The company has a debt-to-equity ratio of 1.56, a current ratio of 0.88 and a quick ratio of 0.67. The company has a market capitalization of $45.57 billion, a price-to-earnings ratio of 65.18, a P/E/G ratio of 4.86 and a beta of 0.87. The firm's fifty day moving average price is $35.42 and its two-hundred day moving average price is $33.55. Teva Pharmaceutical Industries Ltd. has a 1 year low of $18.21 and a 1 year high of $39.70.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last announced its earnings results on Tuesday, June 30th. The company reported $0.02 EPS for the quarter. Teva Pharmaceutical Industries had a net margin of 4.08% and a return on equity of 32.64%. The company had revenue of $4.14 billion during the quarter. As a group, analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 1.94 earnings per share for the current fiscal year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company headquartered in Tel Aviv, Israel. The company develops, manufactures and markets generic medicines, innovative specialty medicines, biosimilars, over-the-counter products and active pharmaceutical ingredients. Its portfolio serves a broad range of therapeutic areas, including central nervous system disorders, respiratory conditions, migraine, oncology and movement disorders.

Teva's specialty medicines include treatments for conditions such as multiple sclerosis, migraine and tardive dyskinesia, while its generic medicines business supplies products across numerous therapeutic categories and dosage forms.

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.